Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Virpax Pharmaceuticals, Inc. (VRPX)
USD0.01
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
1055 Westlakes Drive 19312
Berwyn, PA, US
Berwyn, PA, US
CEO
Jatinder Dhaliwal
Website
virpaxpharma.com
IPO
2021-02-17
CIK 1708331 ISIN US9282513053
Description
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an injectable liposomal gel formulated as a local anesthetic for managing post-operative pain. Also in development are Envelta and PES200, both nanotechnology-based intranasal spray drug candidates engineered to deliver metabolically labile peptide drugs directly to the brain. Further candidates comprise AnQlar, an antiviral barrier solution intended to prevent or lessen the severity of human viral infections such as influenza and SARS-CoV-2, and VRP324, an experimental nasal formulation aimed at enhancing the transport of cannabidiol into the brain. Virpax Pharmaceuticals, Inc. was established in 2016 and is based in Berwyn, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.01
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
650
Beta
2.27
Float Shares
1.05M
Free Float %
84.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +2,120.00% | +2,120.00% | +0.91% | -47.14% | +0.91% | -95.22% | -99.99% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Hold
Price Targets & DCF
Current price
0.01
Low
3.00
+26,927.0%
Consensus
3.00
+26,927.0%
Median
3.00
+26,927.0%
High
3.00
+26,927.0%
DCF (Unlevered)
0.36
+3,104.0%
DCF (Levered)
0.36
+3,104.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2025-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
3.00
+26,927.0%
|
Quality scores
Altman Z-Score
-90.78
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-446.7% Q4'24: +79.4% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'24: +558.8% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+263.2% Q4'24: +263.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'24: 0.00× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est.
|
—
— – —
|
56.59M
56.59M – 56.59M
|
97.38M
97.38M – 97.38M
+72.1% YoY
|
50.42M
50.42M – 50.42M
-48.2% YoY
|
| EBITDA |
-11.96M
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-11.96M
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-12.07M
est: -302.06M (+96.0%)
|
-65.94M
est.
|
-53.18M
-53.18M – -53.18M
+19.4% YoY
|
-56.37M
-56.37M – -56.37M
-6.0% YoY
|
-62.75M
-62.75M – -62.75M
-11.3% YoY
|
87.22M
87.22M – 87.22M
+239.0% YoY
|
| SGA |
6.26M
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-70.91
est: -71.00 (+0.1%)
|
-15.50
est.
|
-12.50
-12.50 – -12.50
+19.4% YoY
|
-13.25
-13.25 – -13.25
-6.0% YoY
|
-14.75
-14.75 – -14.75
-11.3% YoY
|
20.50
20.50 – 20.50
+239.0% YoY
|
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
14
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NAME OF REPORTING PERSONS | 928.25M | 9.00% | — | 1.00M | — | 1.00M | OO | Cayman Islands | 2021-09-23 | ↗ |
| 2 | Anthony P. Mack | 2.97M | 25.20% | 2.97M | — | 2.97M | — | IN | (4) Citizenship or Place of Organization | 2022-02-14 | ↗ |
| 3 | Virpax Pharmaceuticals, LLC | 2.73M | 23.30% | 2.73M | — | 2.73M | — | OO | (4) Citizenship or Place of Organization | 2022-02-14 | ↗ |
| 4 | Altium Capital Management, LP | 1.00M | 8.50% | — | 1.00M | — | — | IA, PN | Delaware, United States of America | 2021-09-21 | ↗ |
| 5 | Altium Growth Fund, LP | 1.00M | 8.50% | — | 1.00M | — | — | PN | Delaware, United States of America | 2021-09-21 | ↗ |
| 6 | Altium Growth GP, LLC | 1.00M | 8.50% | — | 1.00M | — | — | OO | Delaware, United States of America | 2021-09-21 | ↗ |
| 7 | Heights Capital Management, Inc. | 1.00M | 8.50% | — | 1.00M | — | 1.00M | CO | Cayman Islands | 2021-09-20 | ↗ |
| 8 | Kepos Capital LP | 750.0K | 6.40% | — | 750.0K | — | — | IA, PN | Delaware | 2022-02-04 | ↗ |
| 9 | Mark Carhart | 750.0K | 6.40% | — | 750.0K | — | — | IN | United States | 2022-02-04 | ↗ |
| 10 | Daniel B. Asher | 110.7K | 4.99% | — | 110.7K | — | 110.7K | HC, IN | United States of America | 2024-05-23 | ↗ |
| 11 | Intracoastal Capital LLC | 110.7K | 4.99% | — | 110.7K | — | 110.7K | OO | United States of America | 2024-05-23 | ↗ |
| 12 | Mitchell P. Kopin | 110.7K | 4.99% | — | 110.7K | — | 110.7K | HC, IN | United States of America | 2024-05-23 | ↗ |
| 13 | CVI Investments, Inc. | — | 0.00% | — | — | — | — | CO | Cayman Islands | 2022-02-14 | ↗ |
| 14 | Heights Capital Management, Inc. | — | 0.00% | — | — | — | — | CO | Delaware | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
9.00
Bullish
Ratio by volume
3.00
Bullish
Buys
9
Sells
1
Shares acquired
519.0K
Shares disposed
112.0K
Cash buys
—
Cash sales
—
Net activity
+407,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-17 | Panis Jaydriane | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-19 | Randhawa Esha | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-18 | Chaudhry Usama | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-05 | Su Judy | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-05 | Herman Gary L | Director | A-Award | A | Stock Option (right to buy) | 2,500 | 0.58 | 1.4K | 2,500 | — | ↗ |
| 2024-07-05 | Field Katharyn | Director | A-Award | A | Stock Option (right to buy) | 2,500 | 0.58 | 1.4K | 2,500 | — | ↗ |
| 2024-07-05 | Dhaliwal Jatinder | Director | A-Award | A | Stock Option (right to buy) | 2,500 | 0.58 | 1.4K | 2,500 | — | ↗ |
| 2024-01-29 | Singh Vanila | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.32 | 7.9K | 25,000 | — | ↗ |
| 2024-01-29 | Shah Vinay | Officer | A-Award | A | Stock Option (right to buy) | 112,000 | 0.32 | 35.6K | 112,000 | — | ↗ |
| 2024-01-29 | Sendrow Jerrold | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.32 | 7.9K | 25,000 | — | ↗ |
| 2024-01-29 | Ruskin Barbara | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.32 | 7.9K | 25,000 | — | ↗ |
| 2024-01-29 | Mathias Sheila | Officer | A-Award | A | Stock Option (right to buy) | 112,000 | 0.32 | 35.6K | 112,000 | — | ↗ |
| 2024-01-29 | Jambulingam Thani | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.32 | 7.9K | 25,000 | — | ↗ |
| 2024-01-29 | Floyd Eric | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 0.32 | 14.3K | 45,000 | — | ↗ |
| 2024-01-29 | Dubin Michael F | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.32 | 7.9K | 25,000 | — | ↗ |
| 2024-01-29 | Bruce Gerald W | Director / Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 0.32 | 39.7K | 125,000 | — | ↗ |
| 2024-01-25 | Mathias Sheila | Officer | — | D | Stock Option (Right to buy) | 112,000 | 0.79 | 88.5K | 0 | — | ↗ |
| 2023-06-20 | Shah Vinay | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 0.99 | 99.0K | 100,000 | — | ↗ |
| 2023-04-24 | Bruce Gerald W | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.73 | 73.0K | 100,000 | — | ↗ |
| 2023-03-24 | Ruskin Barbara | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-01-31 | Mathias Sheila | Officer | — | D | Stock Option (Right to buy) | 60,676 | 2.13 | 129.2K | 0 | — | ↗ |
| 2023-01-25 | Mack Anthony P. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 125,000 | 0.87 | 108.4K | 125,000 | — | ↗ |
| 2023-01-25 | Gudin Jeffrey | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-01-25 | Chipman Christopher Michael | Officer | A-Award | A | Stock Option (right to buy) | 112,000 | 0.00 | — | 112,000 | — | ↗ |
| 2023-01-01 | Singh Vanila | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2023-01-01 | Sendrow Jerrold | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2023-01-01 | Jambulingam Thani | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-01 | Floyd Eric | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2023-01-01 | Dubin Michael F | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-24 | Sendrow Jerrold | Director | P-Purchase | A | Common Stock, $0.00001 par value | 4,500 | 1.29 | 5.8K | 9,006 | — | ↗ |
| 2022-05-18 | Mack Anthony P. | Officer | P-Purchase | A | Common Stock, $0.00001 par value | 75,750 | 1.34 | 101.5K | 252,562 | — | ↗ |
| 2022-05-18 | Floyd Eric | Director | P-Purchase | A | Common Stock, $0.00001 par value | 4,479 | 1.36 | 6.1K | 8,018 | — | ↗ |
| 2022-04-25 | Bruce Gerald W | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-04-07 | Mathias Sheila | Officer | — | D | Stock Option (Right to buy) | 25,000 | 4.62 | 115.5K | 0 | — | ↗ |
| 2022-01-31 | Mack Anthony P. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 60,676 | 2.13 | 129.2K | 60,676 | — | ↗ |
| 2022-01-31 | Gudin Jeffrey | Director / Officer | A-Award | A | Stock Option (right to buy) | 60,676 | 2.13 | 129.2K | 60,676 | — | ↗ |
| 2022-01-31 | Chipman Christopher Michael | Officer | A-Award | A | Stock Option (right to buy) | 60,676 | 2.13 | 129.2K | 60,676 | — | ↗ |
| 2022-01-01 | Singh Vanila | Director | A-Award | A | Stock Option (right to buy) | 12,091 | 3.43 | 41.5K | 12,091 | — | ↗ |
| 2022-01-01 | Sendrow Jerrold | Director | A-Award | A | Stock Option (right to buy) | 12,091 | 3.43 | 41.5K | 12,091 | — | ↗ |
| 2022-01-01 | Jambulingam Thani | Director | A-Award | A | Stock Option (right to buy) | 14,113 | 3.43 | 48.4K | 14,113 | — | ↗ |
| 2022-01-01 | JACOB GARY S | Director | A-Award | A | Stock Option (right to buy) | 12,091 | 3.43 | 41.5K | 12,091 | — | ↗ |
| 2022-01-01 | Floyd Eric | Director | A-Award | A | Stock Option (right to buy) | 15,124 | 3.43 | 51.9K | 15,124 | — | ↗ |
| 2022-01-01 | Dubin Michael F | Director | A-Award | A | Stock Option (right to buy) | 12,091 | 3.43 | 41.5K | 12,091 | — | ↗ |
| 2021-11-22 | Sendrow Jerrold | Director | P-Purchase | A | Common Stock, $0.00001 par value | 3,900 | 3.93 | 15.3K | 4,506 | — | ↗ |
| 2021-11-18 | Mack Anthony P. | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value | 25,125 | 3.99 | 100.2K | 176,812 | — | ↗ |
| 2021-07-26 | Dubin Michael F | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-26 | Bruce Gerald W | Director | — | D | Common Stock, $0.00001 par value per share | 0 | 0.00 | — | 4,045 | — | ↗ |
| 2021-06-15 | Singh Vanila | Director | — | D | Stock Option (right to buy) | 20,225 | 9.89 | 200.0K | 0 | — | ↗ |
| 2021-05-22 | Mack Anthony P. | Director / Officer | — | D | Stock Option (right to buy) | 40,450 | 9.89 | 400.1K | 0 | — | ↗ |
| 2021-05-22 | Gudin Jeffrey | Director / Officer | — | D | Stock Option (right to buy) | 30,338 | 9.89 | 300.0K | 0 | — | ↗ |
| 2021-05-01 | Sendrow Jerrold | Director | — | D | Stock Option (right to buy) | 2,022 | 9.89 | 20.0K | 0 | — | ↗ |
| 2021-04-26 | JACOB GARY S | Director | — | D | Stock Option (right to buy) | 20,225 | 9.89 | 200.0K | 0 | — | ↗ |
| 2021-04-07 | Singh Vanila | Director | A-Award | A | Stock Option (right to buy) | 8,183 | 4.62 | 37.8K | 8,183 | — | ↗ |
| 2021-04-07 | Sendrow Jerrold | Director | A-Award | A | Stock Option (right to buy) | 10,205 | 4.62 | 47.1K | 10,205 | — | ↗ |
| 2021-04-07 | Mack Anthony P. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 50,000 | 4.62 | 231.0K | 50,000 | — | ↗ |
| 2021-04-07 | Jambulingam Thani | Director | A-Award | A | Stock Option (right to buy) | 10,205 | 4.62 | 47.1K | 10,205 | — | ↗ |
| 2021-04-07 | JACOB GARY S | Director | A-Award | A | Stock Option (right to buy) | 13,183 | 4.62 | 60.9K | 13,183 | — | ↗ |
| 2021-04-07 | Gudin Jeffrey | Director / Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 4.62 | 231.0K | 50,000 | — | ↗ |
| 2021-04-07 | Floyd Eric | Director | A-Award | A | Stock Option (right to buy) | 11,216 | 4.62 | 51.8K | 11,216 | — | ↗ |
| 2021-04-07 | Chipman Christopher Michael | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 4.62 | 115.5K | 25,000 | — | ↗ |
| 2021-04-04 | Bruce Gerald W | Director | — | D | Stock Option (right to buy) | 30,000 | 4.62 | 138.6K | 0 | — | ↗ |
| 2021-03-11 | Bruce Gerald W | Director | — | — | Stock Option (right to buy) | 15,169 | 9.89 | 150.0K | 0 | D | ↗ |
| 2021-02-17 | Jambulingam Thani | Director | P-Purchase | A | Common Stock, $0.00001 par value | 100 | 7.16 | 716.00 | 100 | — | ↗ |
| 2021-02-17 | JACOB GARY S | Director | P-Purchase | A | Common Stock, $0.00001 par value | 3,500 | 6.79 | 23.8K | 3,500 | — | ↗ |
| 2021-02-16 | Virpax Pharmaceuticals LLC | 10% Owner | — | D | Common Stock, $0.00001 par value per share | 0 | 0.00 | — | 2,730,438 | — | ↗ |
| 2021-02-16 | Sendrow Jerrold | Director | — | D | Common Stock, $0.00001 par value per share | 0 | 0.00 | — | 606 | — | ↗ |
| 2021-02-16 | Mack Anthony P. | Director / Officer | — | I | Common Stock, $0.00001 par value per share | 0 | 0.00 | — | 2,730,438 | — | ↗ |
| 2021-02-16 | Gudin Jeffrey | Director / Officer | — | D | Common Stock, $0.00001 par value per share | 0 | 0.00 | — | 7,584 | — | ↗ |
| 2021-02-16 | Floyd Eric | Director | — | D | Common Stock, $0.00001 par value per share | 0 | 0.00 | — | 3,539 | — | ↗ |
| 2021-02-16 | Chipman Christopher Michael | Officer | — | I | Stock Option (right to buy) | 40,450 | 9.89 | 400.1K | 0 | — | ↗ |
| 2021-02-16 | Bruce Gerald W | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-01 | Jambulingam Thani | Director | — | D | Stock Option (right to buy) | 6,697 | 9.89 | 66.2K | 0 | — | ↗ |
| 2021-01-01 | Floyd Eric | Director | — | D | Stock Option (right to buy) | 9,730 | 9.89 | 96.2K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
1.24M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Anthony Mack Former Chief Executive Officer, Chairman | 445.0K | — | — | 60.0K | — | 711.0K | 1.22M | 4.93% | ↗ |
| 2 | 2023 | Sheila A. Mathias PhD, JD Chief Scientific Officer | 308.0K | 115.0K | — | 75.0K | — | — | 498.0K | 15.06% | ↗ |
| 3 | 2023 | Christopher Chipman Former Chief Financial Officer | 169.0K | — | — | 75.0K | — | 247.0K | 491.0K | 15.27% | ↗ |
| 4 | 2023 | Vinay Shah Chief Financial Officer | 123.0K | 115.0K | — | 86.0K | — | — | 324.0K | 26.54% | ↗ |
| 5 | 2023 | Vinay Shah Former Chief Financial Officer | 123.0K | 115.0K | — | 86.0K | — | — | 324.0K | 26.54% | ↗ |
| 6 | 2023 | Gerald W. Bruce Chief Executive Officer | 38.0K | 29.0K | — | 61.0K | — | — | 128.0K | 47.66% | ↗ |
| 7 | 2023 | Gerald W. Bruce Former Chief Executive Officer | 38.0K | 29.0K | — | 61.0K | — | — | 128.0K | 47.66% | ↗ |
| 8 | 2022 | Anthony Mack Former Chief Executive Officer, Chairman | 467.0K | 238.0K | — | 79.0K | — | — | 784.0K | 10.08% | ↗ |
| 9 | 2022 | Christopher Chipman Former Chief Financial Officer | 296.0K | 90.0K | — | 81.0K | — | — | 467.0K | 17.34% | ↗ |
| 10 | 2021 | Anthony Mack Chief Executive Officer | 375.0K | 225.0K | — | 158.0K | — | — | 758.0K | 20.84% | ↗ |
| 11 | 2021 | Christopher Chipman Chief Financial Officer | 236.0K | 100.0K | — | 79.0K | — | — | 415.0K | 19.04% | ↗ |
| 12 | 2021 | Jeffrey Gudin, MD Executive VP, Chief Medical Officer | 100.0K | 45.0K | — | 158.0K | — | — | 303.0K | 52.15% | ↗ |
| 13 | 2020 | Anthony Mack Chief Executive Officer | 375.0K | — | — | 230.0K | — | — | 605.0K | 38.02% | ↗ |
| 14 | 2020 | Christopher Chipman Chief Financial Officer | 48.0K | — | — | 228.0K | — | — | 276.0K | 82.61% | ↗ |
| 15 | 2020 | Jeffrey Gudin, MD Executive VP, Chief Medical Officer | — | — | — | 173.0K | — | — | 173.0K | 100.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sheila A. Mathias | Chief Scientific Officer | 340.0K | — |
| Jatinder Dhaliwal | Interim Chief Financial Officer, Chief Executive Officer & Director | 47.0K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VRPX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
